Accurate calibration determines the fidelity of a quantum system; however, a full calibration routine is a time-consuming ...

A mid-sized manufacturing client came to us with a familiar pain point. Their production floor had no real-time visibility into equipment status. When a conveyor motor overheated or a compressor ...

A group claiming to represent California fire survivors began sending mailers and paying for social media ads this spring, ...

NTSB prelim: NetJets Citation Latitude near Laredo had vibration, right-side fuel/electrical alerts, then dual engine flameout on final. Landed on highway; 1 dead. Fuel tube and starter-gen damage ...

In the wake of a recent safety scare in a confirmatory trial of its antibody-drug conjugate Zynlonta, ADC Therapeutics is tightening its belt in an effort to get the most out of its cancer med. On ...

Edge Computing and Embedded Systems constitute a critical research field at the intersection of hardware design, network architecture, and intelligent software systems. Edge computing refers to the ...

As enterprises race to scale AI, the biggest obstacle to performance and ROI may be the infrastructure moving data, not the hardware processing it. Enterprise AI has entered a new phase. For the past ...

Enterprise AI teams have spent years solving for compute, securing GPU allocations, negotiating cloud capacity, and benchmarking training throughput. The assumption embedded in that work is that the ...

In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma, casting doubt on its value as a ...

Copyright 2026 The Associated Press. All Rights Reserved. Copyright 2026 The Associated Press. All Rights Reserved. Iowa’s waterways face significant pollution ...

Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised questions about the antibody-drug conjugate (ADC), which has been on the market ...

Antibody drug conjugates continue to be a robust area for research and dealmaking, and Eli Lilly’s latest move in this space is the acquisition of CrossBridge Bio, a preclinical startup with ...